跳到主要內容

臺灣博碩士論文加值系統

(44.212.99.248) 您好!臺灣時間:2023/01/28 11:04
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:湯鎧瑋
研究生(外文):Kai-Wei Tang
論文名稱:設計、合成新型Thalidomide衍生物及評估抗發炎活性
論文名稱(外文):Design, Synthesis and Anti-inflammatory Activity Evaluation of Novel Thalidomide Derivatives
指導教授:曾志華曾志華引用關係
指導教授(外文):Chih-Hua Tseng
口試委員:王泰吉楊世群
口試委員(外文):Tai-Chi WangShyh-Chyun Yang
學位類別:碩士
校院名稱:高雄醫學大學
系所名稱:藥學系碩士班
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2017
畢業學年度:105
語文別:中文
論文頁數:101
中文關鍵詞:Thaliodomide衍生物抗發炎
外文關鍵詞:Thalidomide DerivativesAnti-inflammatory
相關次數:
  • 被引用被引用:0
  • 點閱點閱:18
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
Thalidomide為glutamic acid的合成衍生物,目前已被研究出具有多種藥理機轉,像是抗發炎、抗血管增生以及免疫調節的作用,現今多用於治療多種癌症及免疫性疾病,但臨床上仍然有許多副作用需改善。本研究的目的為設計、合成出新一代thalidomide的衍生物,針對glutarimide ring上作修飾,在氮原子上藉由一段spacer連接疏水性基團,並探討其抗發炎活性。其中,我們發現化合物38針對IL-6以及TNF-兼具有高度的抑制效果。未來我們將繼續針對化合物38研究出更詳細的藥理機轉,或將其衍生,希望能開發出具有低副作用、高度抗發炎活性潛力之藥物。
Thalidomide, a synthetic glutamic acid derivative, have been demonstrated to possess various pharmacological effects such as anti-inflammatory, anti-angiogenetic, and immunomodulatory activities. It is widely used nowadays in clinical to treat cancers and immunology diseases. There are, however, still a lot of side effects exhibited by the treatment of thalidomide, including severe teratogenicity which needed to be improved. In this study, we have designed and synthesized novel thalidomide derivatives, which added different substituted aryl groups to glutarimide ring on the thalidomide through different type of spacers. Among them, compound 38 demonstrated an excellent inhibition in both IL-6 and TNF-. We believe that compound 38 can serve as an excellent lead for further development of potential drug candidates.
表目錄 III
圖目錄 IV
中文摘要 1
英文摘要 2
壹、 緒論 3
貳、 研究動機 9
參、 合成方法、結果與討論 15
一、 Thalidomide衍生物的逆合成分析 15
二、 Thalidomide衍生物之合成實驗結果與討論 18
肆、 體外抗發炎活性結果與討論 25
一、 體外抗發炎活性結果 25
二、 結構活性關係討論 33
伍、 結論 35
陸、 實驗部分 36
一、 溶劑及處理過程 36
二、 儀器 37
三、 試藥 38
四、 各化合物之製備 41
柒、 參考文獻 89
1.Randall, T. Thalidomide has 37-year history. JAMA 1990, 263, 1474.
2.Koren , G.;Pastuszak , A.;Ito , S. Drugs in Pregnancy. N Engl J Med 1998, 338, 1128-37.
3.Sheskin, J. Thalidomide in the Treatment of Lepra Reactions. Clin Pharmacol Ther 1965, 6, 303-6.
4.Sampaio, E. P.;Kaplan, G.;Miranda, A.;Nery, J. A.;Miguel, C. P.;Viana, S. M.;Sarno, E. N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993, 168, 408-14.
5.Zwingenberger, K.;Wnendt, S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflamm 1995, 46, 177-211.
6.Rajkumar, S. V.;Blood, E.;Vesole, D.;Fonseca, R.;Greipp, P. R.;Eastern Cooperative Oncology, G. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24, 431-6.
7.Eleutherakis-Papaiakovou, V.;Bamias, A.;Dimopoulos, M. A. Thalidomide in cancer medicine. Ann Oncol 2004, 15, 1151-60.
8.Bramuzzo, M.;Ventura, A.;Martelossi, S.;Lazzerini, M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine 2016, 95, 4239-54.
9.Richardson, P.;Hideshima, T.;Anderson, K. Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002, 53, 629-57.
10.D''Amato, R. J.;Loughnan, M. S.;Flynn, E.;Folkman, J. Thalidomide is an inhibitor of angiogenesis. Pro Natl Acad Sci 1994, 91, 4082-85.
11.Mei, S. C.;Wu, R. T. The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. Mol Cancer Ther 2008, 7, 2405-14.
12.Moreira, A. L.;Sampaio, E. P.;Zmuidzinas, A.;Frindt, P.;Smith, K. A.;Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993, 177, 1675-80.
13.Nakamura, T.;Noguchi, T.;Kobayashi, H.;Miyachi, H.;Hashimoto, Y. Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. Chem Pharm Bull (Tokyo) 2006, 54, 1709-14.
14.Keifer, J. A.;Guttridge, D. C.;Ashburner, B. P.;Baldwin, A. S., Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001, 276, 22382-7.
15.Kotla, V.;Goel, S.;Nischal, S.;Heuck, C.;Vivek, K.;Das, B.;Verma, A. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2, 36.
16.Haslett, P. A.;Corral, L. G.;Albert, M.;Kaplan, G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998, 187, 1885-92.
17.Mueller, D. L.;Jenkins, M. K.;Schwartz, R. H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989, 7, 445-80.
18.Stirling, D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001, 28, 602-6.
19.Shortt, J.;Hsu, A. K.;Johnstone, R. W. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 2013, 32, 4191-202.
20.Dienz, O.;Rud, J. G.;Eaton, S. M.;Lanthier, P. A.;Burg, E.;Drew, A.;Bunn, J.;Suratt, B. T.;Haynes, L.;Rincon, M. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol 2012, 5, 258-66.
21.Hoge, J.;Yan, I.;Janner, N.;Schumacher, V.;Chalaris, A.;Steinmetz, O. M.;Engel, D. R.;Scheller, J.;Rose-John, S.;Mittrucker, H. W. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol 2013, 190, 703-11.
22.Hunter, C. A.;Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015, 16, 448-57.
23.Bradley, J. R. TNF-mediated inflammatory disease. J Pathol 2008, 214, 149-60.
24.Zelova, H.;Hosek, J. TNF-alpha signalling and inflammation: interactions between old acquaintances. Inflamm Res 2013, 62, 641-51.
25.Stephens, T. D.;Fillmore, B. J. Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology 2000, 61, 189-95.
26.Neubert R, N. D. Pecularities and possible mode of actions of thalidomide. In: Handbook of Experimental Pharmacology. New York: Springer-Verlag 1997, 41-119.
27.Karrow, N. A.;McCay, J. A.;Brown, R. D.;Musgrove, D. L.;Pettit, D. A.;Munson, A. E.;Germolec, D. R.;White, K. L., Jr. Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol Appl Pharmacol 2000, 165, 237-44.
28.Bastuji-Garin, S.;Ochonisky, S.;Bouche, P.;Gherardi, R. K.;Duguet, C.;Djerradine, Z.;Poli, F.;Revuz, J.;Grp, T. N. S. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002, 119, 1020-26.
29.McBride, W. G. Thalidomide embryopathy. Teratology 1977, 16, 79-82.
30.Zahran, M. A.;Salem, T. A.;Samaka, R. M.;Agwa, H. S.;Awad, A. R. Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice. Bioorg Med Chem 2008, 16, 9708-18.
31.Zahran, M. A.;Abdin, Y. G.;Osman, A. M.;Gamal-Eldeen, A. M.;Talaat, R. M.;Pedersen, E. B. Synthesis and evaluation of thalidomide and phthalimide esters as antitumor agents. Arch Pharm (Weinheim) 2014, 347, 642-9.
32.Hess, S.;Akermann, M. A.;Wnendt, S.;Zwingenberger, K.;Eger, K. Synthesis and immunological activity of water-soluble thalidomide prodrugs. Bioorg Med Chem 2001, 9, 1279-91.
33.Fernandez Brana, M.;Acero, N.;Anorbe, L.;Munoz Mingarro, D.;Llinares, F.;Dominguez, G. Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-alpha production. Eur J Med Chem 2009, 44, 3533-42.
34.Stewart, S. G.;Braun, C. J.;Polomska, M. E.;Karimi, M.;Abraham, L. J.;Stubbs, K. A. Efforts toward elucidating Thalidomide''s molecular target: an expedient synthesis of the first Thalidomide biotin analogue. Org Biomol Chem 2010, 8, 4059-62.
35.Ronnebaum, J. M.;Luzzio, F. A. Synthesis of 1,2,3-triazole ''click'' analogues of thalidomide. Tetrahedron 2016, 72, 6136-41.
36.Murdaca, G.;Spano, F.;Miglino, M.;Puppo, F. Effects of TNF-alpha inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013, 5, 113-5.
37.Neves Filho, R. A.;Westermann, B.;Wessjohann, L. A. Synthesis of (-)-julocrotine and a diversity oriented Ugi-approach to analogues and probes. Beilstein J Org Chem 2011, 7, 1504-7.
38.Temple, C., Jr.;Rener, G. A. Antimitotic agents. Chiral isomers of ethyl [5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido-[3,4-b]pyrazin-7 -yl]carbamate. J Med Chem 1992, 35, 988-93.
39.Luzzio, F. A.;Mayorov, A. V.;Ng, S. S.;Kruger, E. A.;Figg, W. D. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. J Med Chem 2003, 46, 3793-9.
40.Liang, L.;Astruc, D. The copper (I)-catalyzed alkyne-azide cycloaddition (CuAAC)“click” reaction and its applications. An overview. Coordination Chemistry Reviews 2011, 255, 2933-2945.
41.Castro, V.;Rodriguez, H.;Albericio, F. CuAAC: An Efficient Click Chemistry Reaction on Solid Phase. ACS Comb Sci 2016, 18, 1-14.
42.Sirion, U.;Kim, H. J.;Lee, J. H.;Seo, J. W.;Lee, B. S.;Lee, S. J.;Oh, S. J.;Chi, D. Y. An efficient F-18 labeling method for PET study: Huisgen 1, 3-dipolar cycloaddition of bioactive substances and F-18-labeled compounds. Tetrahedron letters 2007, 48, 3953-57.
43.Balci, A.;Arslan, M.;Nixha, A. R.;Bilen, C.;Ergun, A.;Gencer, N. Synthesis and evaluation of N-heteroarylsubstituted triazolosulfonamides as carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2015, 30, 377-82.
44.Rao, D. R.;Κankan, R. N. PROCESSES FOR THE PREPARATION OF THALIDOMIDE. WO 2009/083724 A1 2009.
45.Zhou, S.;Liao, H.;Liu, M.;Feng, G.;Fu, B.;Li, R.;Cheng, M.;Zhao, Y.;Gong, P. Discovery and biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors. Bioorg Med Chem 2014, 22, 6438-52.
46.Liang, S.;Li, H.;Shen, L.;Li, H.;Mao, Z.;Li, H. Measurement and correlation of the solubility of (1-benzyl-1H-1, 2, 3-triazole-4-yl) methanol in water and alcohols at temperatures from 292.15 K to 310.15 K. Thermochimica Acta 2016, 630, 1-10.
47.Kuleshov, K.;Borovkov, K. Y.;Rodin, O.;Perevalov, V. Synthesis of novel 5-piperidyl-substituted 7-hydroxy-3H-1, 2, 3-triazolo [4, 5-d] pyrimidines. Chem Heterocycl Compd (N Y) 2006, 42, 246-260.
48.Patonay, T.;Juhász‐Tóth, É.;Bényei, A. Base‐Induced Coupling of α‐Azido Ketones with Aldehydes− An Easy and Efficient Route to Trifunctionalized Synthons 2‐Azido‐3‐hydroxy Ketones, 2‐Acylaziridines, and 2‐Acylspiroaziridines. Eur J Org Chem 2002, 2002, 285-95.
49.Shi, F.;Waldo, J. P.;Chen, Y.;Larock, R. C. Benzyne click chemistry: synthesis of benzotriazoles from benzynes and azides. Org Lett 2008, 10, 2409-12.
50.Schmitz, J.;Li, T.;Bartz, U.;Gutschow, M. Cathepsin B Inhibitors: Combining Dipeptide Nitriles with an Occluding Loop Recognition Element by Click Chemistry. ACS Med Chem Lett 2016, 7, 211-6.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top